Lantern Pharma (LTRN) AI Stock Analysis

• Market Cap: $42.50M
• Dividend Yield: N/A
• Average Volume (3M): 103.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: N/A
• EPS Growth: 1.18%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 11,184,423
• 10 Day Avg. Volume: 75,328
• 30 Day Avg. Volume: 103,283
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.93
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -581.91
• Enterprise Value/Ebitda: -1.80
• 1Y Price Target: $25.00
• Price Target Upside: 727.81% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.83
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: ―

Lantern Pharma is innovating with AI in oncology, achieving key clinical and regulatory milestones. However, the financial outlook is challenging due to zero revenue and cash flow concerns, necessitating additional funding. Technicals are stable but show potential volatility.

Positive Factors

AI Integration

The integration of AI and machine learning into drug development enhances efficiency and precision, potentially reducing costs and accelerating timelines, which is a significant competitive advantage in the biotechnology sector.

Regulatory Achievements

FDA Fast Track designations can expedite the development and review process, potentially bringing drugs to market faster, which is crucial for addressing unmet medical needs and enhancing future revenue potential.

Strategic Expansion

Expanding clinical trials geographically can increase patient enrollment and diversify market presence, enhancing the company's ability to capture global market opportunities and improve clinical trial outcomes.

Negative Factors

Zero Revenue

The lack of revenue generation highlights the company's reliance on external funding and partnerships, posing a risk to financial sustainability and limiting its ability to self-fund operations and growth initiatives.

Increased Operating Loss

Rising operational losses without corresponding revenue increases strain financial resources, necessitating additional funding and potentially diluting shareholder value if equity financing is pursued.

Funding Needs

The need for significant external funding highlights potential liquidity issues and the risk of financial instability, which could impact the company's ability to sustain operations and invest in growth.

Lantern Pharma Business Overview & Revenue Model

Company Description

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

How the Company Makes Money

Lantern Pharma generates revenue primarily through the development and commercialization of its drug candidates. The company uses its proprietary RADR platform to identify biomarkers and genetic signatures that can predict patient response to its drug candidates, thereby reducing time and cost associated with drug development. Revenue streams include out-licensing partnerships, collaborations with pharmaceutical companies, and potentially, future sales of approved drugs. These partnerships often involve milestone payments, royalties, and shared development costs, which are significant contributors to the company's earnings. As Lantern Pharma advances its drug pipeline and secures additional partnerships, these factors are expected to drive financial growth.

Lantern Pharma Financial Statement Overview

Summary

Lantern Pharma faces significant financial challenges, with zero revenue and increasing operational losses. Despite a strong balance sheet with low debt, the negative cash flow situation raises concerns about long-term viability and the need for additional financing.

Income Statement

Lantern Pharma has consistently reported zero revenue, indicating a pre-revenue stage or significant challenges in generating sales. The company's net losses have increased substantially over the years, reflecting mounting operational challenges. The EBIT and EBITDA margins are negative due to high operational expenses without corresponding revenue, undermining profitability prospects.

Balance Sheet

The company maintains a strong equity position relative to its assets, with a high equity ratio, reflecting financial stability. The debt-to-equity ratio is low, indicating minimal reliance on debt financing, which reduces financial risk. However, the consistent increase in liabilities and decreasing cash reserves could affect future liquidity and operational capacity.

Cash Flow

Lantern Pharma exhibits negative operating and free cash flows, indicating cash burn without revenue inflow. Despite substantial financing inflows in prior years, the inability to generate positive cash flows from operations is concerning. The lack of free cash flow growth highlights potential sustainability challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-59.90K	0.00	-174.84K	0.00	0.00	0.00
EBITDA	-19.41M	-22.20M	-15.79M	-14.42M	-12.58M	-5.90M
Net Income	-18.92M	-20.78M	-15.96M	-14.26M	-12.36M	-5.91M
Balance Sheet
Total Assets	13.63M	25.57M	43.65M	58.84M	73.95M	20.36M
Cash, Cash Equivalents and Short-Term Investments	12.36M	24.01M	41.30M	55.20M	70.73M	19.23M
Total Debt	93.95K	243.66K	234.47K	52.89K	204.95K	108.50K
Total Liabilities	4.04M	4.38M	2.74M	2.80M	2.38M	660.84K
Stockholders Equity	9.59M	21.19M	40.91M	56.04M	71.57M	19.70M
Cash Flow
Free Cash Flow	-16.86M	-17.83M	-14.37M	-12.80M	-10.61M	-5.67M
Operating Cash Flow	-16.86M	-17.81M	-14.35M	-12.77M	-10.59M	-5.65M
Investing Cash Flow	16.21M	3.37M	-930.21K	179.27K	-19.53M	-16.14K
Financing Cash Flow	971.78K	66.71K	-500.00K	-2.18M	63.42M	23.66M

Lantern Pharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LTRN, the sentiment is Neutral. The current price of 3.02 is below the 20-day moving average (MA) of 3.50, below the 50-day MA of 3.93, and below the 200-day MA of 3.83, indicating a neutral trend. The MACD of -0.13 indicates Negative momentum. The RSI at 54.98 is Neutral, neither overbought nor oversold. The STOCH value of 82.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LTRN.

Lantern Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RNXT	49 Neutral	$32.48M	―	-146.61%	―	―	37.89%
LTRN	45 Neutral	$42.50M	―	-104.58%	―	―	1.18%
MAIA	44 Neutral	$36.29M	-1.86	-2691.06%	―	―	44.50%
SKYE	38 Underperform	$42.00M	―	-94.31%	―	―	-53.18%
MDCX	35 Underperform	$45.16M	―	-2287.74%	―	―	-60.01%
BCAB	35 Underperform	$50.01M	-0.74	―	―	-100.00%	32.37%

Lantern Pharma Corporate Events

Lantern Pharma Reports Q4 2024 Financial Results and AI Progress

On March 27, 2025, Lantern Pharma announced its financial results for the fourth quarter and full year ended December 31, 2024, alongside updates on its AI-driven drug candidates and operational progress. The company reported significant advancements in its clinical programs, including the HARMONIC™ trial for LP-300, which showed promising results in never-smoker NSCLC patients, and the continued progress of LP-184 and LP-284 in clinical trials. Lantern Pharma also highlighted its innovative AI capabilities, such as the RADR® platform surpassing 100 billion oncology-specific data points and the development of an AI-powered ADC module, which could significantly reduce development timelines and costs.